PART I Item 1. Busi ness. Company Overview We are a precision medicine oncology company committed to the discovery, development, and commercialization of transformative therapies for cancer. Our approach integrates expertise in small-molecule drug discovery, structural biology and bioinformatics with robust internal capabilities in identifying and validating translational biomarkers to develop tailored, potentially first-in-class targeted therapies aligned to the genetic drivers of disease. We h...
Q2 FY2026 — expected 2026-09-04
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-02-17 | 2025-12-31 | 0001193125-26-054533 | EDGAR | 109K words |
| 2025-02-18 | 2024-12-31 | 0000950170-25-022183 | EDGAR | — |
| 2024-02-20 | 2023-12-31 | 0000950170-24-017093 | EDGAR | — |
| 2023-03-07 | 2022-12-31 | 0000950170-23-006456 | EDGAR | — |
| 2022-03-18 | 2021-12-31 | 0001564590-22-010922 | EDGAR | — |
| 2021-03-23 | 2020-12-31 | 0001564590-21-014676 | EDGAR | — |
| 2020-03-24 | 2019-12-31 | 0001564590-20-012501 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-04 | 2025-09-30 | 0001193125-25-264632 | EDGAR | 26K words |
| 2025-08-05 | 2025-06-30 | 0000950170-25-102967 | EDGAR | — |
| 2025-05-06 | 2025-03-31 | 0000950170-25-064438 | EDGAR | — |
| 2024-11-04 | 2024-09-30 | 0000950170-24-120675 | EDGAR | — |
| 2024-08-06 | 2024-06-30 | 0000950170-24-091823 | EDGAR | — |
| 2024-05-07 | 2024-03-31 | 0000950170-24-054466 | EDGAR | — |
| 2023-11-07 | 2023-09-30 | 0000950170-23-060206 | EDGAR | — |
| 2023-08-10 | 2023-06-30 | 0000950170-23-041394 | EDGAR | — |
| 2023-05-09 | 2023-03-31 | 0000950170-23-019605 | EDGAR | — |
| 2022-11-08 | 2022-09-30 | 0000950170-22-023207 | EDGAR | — |
| 2022-08-15 | 2022-06-30 | 0000950170-22-017204 | EDGAR | — |
| 2022-05-10 | 2022-03-31 | 0000950170-22-008946 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-02-17 | 0001193125-26-052741 | EDGAR | 2K words |
| 2026-01-12 | 0001193125-26-009653 | EDGAR | — |
| 2026-01-12 | 0001193125-26-009641 | EDGAR | — |
| 2025-12-12 | 0001193125-25-317541 | EDGAR | — |
| 2025-12-05 | 0001193125-25-309716 | EDGAR | — |
| 2025-11-04 | 0001193125-25-263383 | EDGAR | — |
| 2025-10-20 | 0001193125-25-243558 | EDGAR | — |
| 2025-09-08 | 0001193125-25-197605 | EDGAR | — |
| 2025-09-02 | 0001193125-25-193238 | EDGAR | — |
| 2025-08-05 | 0000950170-25-102353 | EDGAR | — |
152 total filings indexed. 123 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001676725 |
| Ticker | IDYA |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Website | https://www.ideayabio.com |
| Listed | 2019-05-23 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report